MAPT and Alzheimer disease: Although almost all clinical trials for AD have failed since then, increased government and societal support for basic research in AD has led to significant advances in our understanding of molecular pathways related to AD risk and progression, and a slew of novel agents in different stages of clinical development targeting pathways including Aβ, tau, and inflammation [12].